LyGenesis Inc.
June 22, 2026
Theater 1
Type: Company Presentation
Focus Area:
Regenerative Medicine
LyGenesis is a clinical-stage biotechnology company developing a novel cell therapy platform leveraging patients' lymph nodes as bioreactors to grow functioning ectopic organs. LyGenesis' lead allogeneic cell therapy program is currently in a Phase 2a clinical trial for patients with end-stage liver disease (ClinicalTrials.gov Identifier: NCT04496479). LyGenesis' cell therapy platform including therapies in development designed to produce an ectopic thymus (for aging and multiple other potential indications), pancreas (for Type 1 diabetes), and kidney (for renal disease). Privately held, LyGenesis is headquartered in Pittsburgh, Pennsylvania. To learn more, please visit our website at www.LyGenesis.com
Company HQ City:
Pittsburgh
Company HQ State:
Pennsylvania
Company HQ Country:
United States
Year Founded:
2017
Lead Product in Development:
LYG-LIV-001 is an allogeneic cell therapy regulated by the FDA as a Section 351 Human Cellular Therapy/Product and as an investigational biologic product. This biologic therapy is created starting from donated otherwise unmatched livers. A complex, multi-step Current Good Manufacturing Practices process carefully isolates and suspends hepatocytes in a solution to ready them for transplantation into that patient's upper abdominal lymph nodes using an endoscopic ultrasound, a minimally invasive approach. The lymph nodes then act an as in vivo bioreactors, helping the hepatocytes to engraft, proliferate, and generate functional ectopic liver tissue. LyGenesis' cell therapies do not involve genetic engineering, which reduces the time, risks, and costs associated with manufacturing and commercializing their therapies.
CEO
Michael Hufford, PhD
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
4
When you expect your next catalyst update?
September 2026
What is your next catalyst (value inflection) update?
Completion of cohort 2 of our Clinical Trial (ClinicalTrials.gov Identifier: NCT04496479) and commencing our DSMB
Primary Speaker
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}